BACKGROUND: We analyzed the treatment patterns and safety outcomes of the most common first-line platinum-based regimens initiated on or after non-small cell lung cancer (NSCLC) diagnosis in a real-world setting. METHODS: Based on a United States oncology electronic medical record (EMR) database, patients treated with first-line platinum-based regimens after advanced NSCLC diagnosis from September 2008 to November 2014 were analyzed. Baseline characteristics and selected adverse events during treatment [incidence proportions and incidence rates (IRs)] were described by regimen. Propensity score stratification was used to adjust for baseline characteristics differences. Hazard ratios (HRs) were estimated using Cox proportional hazards model, with paclitaxel (Pac)/carboplatin (Carbo) as reference. Subgroup analysis was conducted for elderly patients (≥70 years old). RESULTS: The most common five regimens for the eligible patients were as follows: Pac/Carbo (n=3,009), pemetrexed (Pem)/Carbo (n=1,625), Pem/Carbo/bevacizumab (Bev) (n=735), Pac/Carbo/Bev (n=531), Pem/cisplatin (Cis) (n=357), and docetaxel (Doc)/Carbo (n=355). Highest IRs were reported for anemia, neutropenia, nausea, and vomiting across these regimens in patients of all ages. After propensity score stratification, compared with Pac/Carbo, risk of anemia was significantly lower with Pac/Carbo/Bev (HR =0.67), Pem/Cis (HR =0.68), and Pem/Carbo/Bev (HR =0.82); risk of neutropenia was comparable among all regimens except Doc/Carbo (significantly lower risk; HR =0.72); and risk of nausea (HR =1.45) and vomiting (HR =1.50) was significantly higher with Pem/Cis. Safety outcomes in elderly patients were consistent with the overall population. CONCLUSIONS: While EMR data have limitations, the real-world safety outcome with individual chemotherapy regimen could be considered for the better selection of platinum-based therapies in NSCLC. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: We analyzed the treatment patterns and safety outcomes of the most common first-line platinum-based regimens initiated on or after non-small cell lung cancer (NSCLC) diagnosis in a real-world setting. METHODS: Based on a United States oncology electronic medical record (EMR) database, patients treated with first-line platinum-based regimens after advanced NSCLC diagnosis from September 2008 to November 2014 were analyzed. Baseline characteristics and selected adverse events during treatment [incidence proportions and incidence rates (IRs)] were described by regimen. Propensity score stratification was used to adjust for baseline characteristics differences. Hazard ratios (HRs) were estimated using Cox proportional hazards model, with paclitaxel (Pac)/carboplatin (Carbo) as reference. Subgroup analysis was conducted for elderly patients (≥70 years old). RESULTS: The most common five regimens for the eligible patients were as follows: Pac/Carbo (n=3,009), pemetrexed (Pem)/Carbo (n=1,625), Pem/Carbo/bevacizumab (Bev) (n=735), Pac/Carbo/Bev (n=531), Pem/cisplatin (Cis) (n=357), and docetaxel (Doc)/Carbo (n=355). Highest IRs were reported for anemia, neutropenia, nausea, and vomiting across these regimens in patients of all ages. After propensity score stratification, compared with Pac/Carbo, risk of anemia was significantly lower with Pac/Carbo/Bev (HR =0.67), Pem/Cis (HR =0.68), and Pem/Carbo/Bev (HR =0.82); risk of neutropenia was comparable among all regimens except Doc/Carbo (significantly lower risk; HR =0.72); and risk of nausea (HR =1.45) and vomiting (HR =1.50) was significantly higher with Pem/Cis. Safety outcomes in elderly patients were consistent with the overall population. CONCLUSIONS: While EMR data have limitations, the real-world safety outcome with individual chemotherapy regimen could be considered for the better selection of platinum-based therapies in NSCLC. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: Nick Thatcher; Fred R Hirsch; Alexander V Luft; Aleksandra Szczesna; Tudor E Ciuleanu; Mircea Dediu; Rodryg Ramlau; Rinat K Galiulin; Beatrix Bálint; György Losonczy; Andrzej Kazarnowicz; Keunchil Park; Christian Schumann; Martin Reck; Henrik Depenbrock; Shivani Nanda; Anamarija Kruljac-Letunic; Raffael Kurek; Luis Paz-Ares; Mark A Socinski Journal: Lancet Oncol Date: 2015-06-01 Impact factor: 41.316
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Elizabeth M Blanchard; James Moon; Paul J Hesketh; Karen Kelly; Antoinette J Wozniak; John Crowley; David Gandara Journal: J Thorac Oncol Date: 2011-01 Impact factor: 15.609
Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245
Authors: Suresh S Ramalingam; Suzanne E Dahlberg; Corey J Langer; Robert Gray; Chandra P Belani; Julie R Brahmer; Alan B Sandler; Joan H Schiller; David H Johnson Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544
Authors: Corey J Langer; Mark A Socinski; Jyoti D Patel; Alan B Sandler; Joan H Schiller; Larry Leon; Sebastien J Hazard; Suresh S Ramalingam Journal: Am J Clin Oncol Date: 2016-10 Impact factor: 2.339
Authors: Alessia E Russo; Domenico Priolo; Giovanna Antonelli; Massimo Libra; James A McCubrey; Francesco Ferraù Journal: Lung Cancer (Auckl) Date: 2017-12-14
Authors: Tina Lamy; Bastien Cabarrou; David Planchard; Xavier Quantin; Sophie Schneider; Michael Bringuier; Benjamin Besse; Nicolas Girard; Christos Chouaid; Thomas Filleron; Gaëtane Simon; Capucine Baldini Journal: Cancers (Basel) Date: 2021-12-24 Impact factor: 6.639